<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028404</url>
  </required_header>
  <id_info>
    <org_study_id>NN1952-3646</org_study_id>
    <secondary_id>U1111-1112-2892</secondary_id>
    <secondary_id>2009-013282-26</secondary_id>
    <nct_id>NCT01028404</nct_id>
  </id_info>
  <brief_title>A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes</brief_title>
  <official_title>A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0148-0000-0106 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the safety,&#xD;
      tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 as&#xD;
      tablets in healthy volunteers and subjects with type 1 and type 2 diabetes.&#xD;
&#xD;
      The trial consists of two parts. In part 1, single escalating doses of NN1952, placebo or&#xD;
      insulin aspart will be given to healthy volunteers. In part 2, subjects with type 1 or type 2&#xD;
      diabetes will receive single doses of NN1952 (with/without a meal), insulin aspart and&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse events for trial part 1</measure>
    <time_frame>from visit 1 to visit 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and severity of adverse events for trial part 2</measure>
    <time_frame>from visit 1 to visit 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin concentration-time curve after a single dose</measure>
    <time_frame>after 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate-time curve after a single dose</measure>
    <time_frame>after 12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Trial part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NN1952</intervention_name>
    <description>Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.</description>
    <arm_group_label>Trial part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.</description>
    <arm_group_label>Trial part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.</description>
    <arm_group_label>Trial part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NN1952</intervention_name>
    <description>Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.</description>
    <arm_group_label>Trial part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.</description>
    <arm_group_label>Trial part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.</description>
    <arm_group_label>Trial part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FOR TRIAL PART 1, THE FOLLOWING APPLIES:&#xD;
&#xD;
          -  Gender: male&#xD;
&#xD;
          -  Age: 18-55 years&#xD;
&#xD;
          -  BMI (body mass index): 18-28 kg/m2&#xD;
&#xD;
          -  Study participants considered to be healthy&#xD;
&#xD;
          -  FOR TRIAL PART 2, THE FOLLOWING APPLIES:&#xD;
&#xD;
          -  Gender: male or female of no childbearing potential&#xD;
&#xD;
          -  Age: 18-65 years&#xD;
&#xD;
          -  Type 1 diabetes: BMI (body mass index): 18-28 kg/m2&#xD;
&#xD;
          -  Type 2 diabetes: BMI (body mass index): 22-35 kg/m2&#xD;
&#xD;
          -  Type 1 or type 2 diabetes for at least 12 months&#xD;
&#xD;
          -  Type 1 diabetes: Treatment with insulin for at least 12 months&#xD;
&#xD;
          -  Type 2 diabetes: Treatment with insulin for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected allergy to the trial product or related products&#xD;
&#xD;
          -  Presence of illness or infection that may confound the results of the study or pose a&#xD;
             risk to the study participant by dosing NN1952, as judged by the Investigator&#xD;
&#xD;
          -  Presence of acute gastrointestinal symptoms (for example nausea, vomiting, heartburn&#xD;
             or diarrhoea)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>December 7, 2009</study_first_submitted>
  <study_first_submitted_qc>December 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

